Complete tumor response of a locally advanced lung large-cell neuroendocrine carcinoma after palliative thoracic radiotherapy and immunotherapy with nivolumab

Autor: Vincent Remouchamps, Claudia Pop-Stanciu, Myriam Remmelink, Marie Wanet, Lionel Pirard, Michaël Dupont, Charlotte Mauclet, Nicky D'Haene, Suzan Lambin, Benoît Rondelet, Thierry Vander Borght, Fabrice Duplaquet, Sebahat Ocak
Přispěvatelé: UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de pneumologie, UCL - (MGD) Service d'oncologie médicale, UCL - (MGD) Service de chirurgie cardio-vasculaire et thoracique, UCL - (MGD) Service de radiologie - résonance magnétique, UCL - (MGD) Service d'anatomie pathologique, UCL - (MGD) Service de médecine nucléaire, UCL - (MGD) Autre
Jazyk: angličtina
Rok vydání: 2019
Předmět:
0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
Adult
Cancer Research
medicine.medical_specialty
Lung Neoplasms
medicine.medical_treatment
Thoracic radiotherapy
Locally advanced
Tumor response
03 medical and health sciences
0302 clinical medicine
Internal medicine
Positron Emission Tomography Computed Tomography
Locally advanced stage
Antineoplastic Combined Chemotherapy Protocols
medicine
Carcinoma
Humans
Salvage surgery
Neoplasm Metastasis
Neoplasm Staging
Lung
business.industry
Palliative Care
Immunotherapy
medicine.disease
Lung large-cell neuroendocrine carcinoma
Combined Modality Therapy
Immunohistochemistry
Carcinoma
Neuroendocrine
PD-1 inhibitor
Radiation therapy
030104 developmental biology
medicine.anatomical_structure
Nivolumab
030220 oncology & carcinogenesis
Synergistic effect
Carcinoma
Large Cell
Female
Radiotherapy
Adjuvant
Human medicine
business
Zdroj: Lung cancer: journal of the International Association for the Study of Lung Cancer
Lung cancer, Vol. 128, p. 53-56 (2019)
ISSN: 0169-5002
Popis: Lung large-cell neuroendocrine carcinoma (L-LCNEC) is a rare subset of lung carcinoma associated with poor overall survival. Due to its rarity, little has been established about its optimal treatment in the advanced stage. We report the case of a 41-year-old woman diagnosed with an unresectable locally advanced L-LCNEC who presented an impressive tumor response to immunotherapy with nivolumab after non-curative thoracic radiotherapy. Salvage surgery was then performed, and pathologic analysis of the resected piece revealed the absence of residual viable tumor cells. Based on this case report, we discuss the literature regarding the efficacy of inhibitors of programmed death-1 protein (PD-1) in L-LCNEC and their use in association with radiotherapy and in the neoadjuvant setting.
Databáze: OpenAIRE
Externí odkaz: